i want to bring in our guests to break down this market action, mark suzuki of bank of america merrillynch. what is going on with biotech? last fewhink over the months and years, you have seen more and more investors pile into these crowded areas of the market area what you are starting to see right now is there is cracks in that leadership. we look historically at stocks, roughly 40% of those stocks grow into their multiple and do well. that means the other 60% actually don't do well and a lot of them end up pretty ugly. when you saw with this run you've had in biotech stocks, they are basically priced for most of them doing well, not priced for 60% of them not working out. joe: the ceo of glencore lost $500 million today just breaking through the terminal. alix: that's a bad day. joe: a lot of these companies, if you're on a pe basis -- when you see these really speculative areas, how far can they fall? p i don't tend to look at multiples for these types of stocks. a lot of them don't even have earnings today. you are buying what they're going to do why for 10 years in the future. yo